China SXT Pharmaceuticals, Inc. SXTC
· IPO 2019 · data as of November 13, 2026
China SXT Pharmaceuticals, Inc. (SXTC) is a company listed in the US with a market value of about $310725. In fiscal year 2026 it had revenue of $1M and net income of -$6M, a net margin of -545.2%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -25% a year, a 5-year average ROIC of -20%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 60% below the current price.
About China SXT Pharmaceuticals
China SXT Pharmaceuticals is listed in the US, IPO year 2019. Revenue went from $5M in 2017 to $1M in 2026, a decline of about 14.9% a year. It was profitable in 3 of the last 10 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $2M | $2M | $2M | $3M | $5M | $5M | $7M | $7M | $5M |
| Net income | -$6M | -$3M | -$3M | -$6M | -$6M | -$3M | -$10M | $2M | $1M | $1M |
| Free cash flow | — | -$2M | -$2M | — | $207361 | -$1M | $803408 | -$296633 | $1M | $113866 |
| EPS (diluted) | $-59.91 | $-31.90 | $-29.92 | $-57.30 | $-55.38 | $-26.53 | $-99.33 | $14.86 | $11.47 | $11.44 |
| Net margin | -545.2% | -189.8% | -160.7% | -301.0% | -220.4% | -57.5% | -199.3% | 21.9% | 16.9% | 24.3% |
| ROIC | -18.2% | -12.9% | -13.4% | -28.6% | -25.5% | -12.8% | -14.1% | 13.6% | 32.4% | 64.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is China SXT Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 60% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does China SXT Pharmaceuticals pay a dividend?
Not currently.
Is China SXT Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. China SXT Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.